Several monoclonal antibodies targeting CTLA-4 and PD-1/PD-L1 have been approved to treat advanced melanoma and various malignant tumors which significantly prolonged patient survival (Hargadon et al., 2018; Bai et al., 2021; Carlino et al., 2021). This evidence concerns the gene CD274 and melanoma.